Morgan Stanley’s Pacira BioSciences PCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $31.5M | Buy |
1,392,548
+199,954
| +17% | +$4.44M | ﹤0.01% | 2535 |
|
|
2025
Q4 | $30.9M | Buy |
1,192,594
+49,832
| +4% | +$1.18M | ﹤0.01% | 2540 |
|
|
2025
Q3 | $29.4M | Buy |
1,142,762
+192,726
| +20% | +$4.73M | ﹤0.01% | 2510 |
|
|
2025
Q2 | $22.7M | Sell |
950,036
-47,570
| -5% | -$1.2M | ﹤0.01% | 2673 |
|
|
2025
Q1 | $24.8M | Sell |
997,606
-107,168
| -10% | -$2.57M | ﹤0.01% | 2475 |
|
|
2024
Q4 | $20.8M | Sell |
1,104,774
-491,115
| -31% | -$8.62M | ﹤0.01% | 2712 |
|
|
2024
Q3 | $24M | Buy |
1,595,889
+1,079,724
| +209% | +$18.5M | ﹤0.01% | 2616 |
|
|
2024
Q2 | $14.8M | Sell |
516,165
-154,162
| -23% | -$4.39M | ﹤0.01% | 2987 |
|
|
2024
Q1 | $19.6M | Sell |
670,327
-700,341
| -51% | -$21.5M | ﹤0.01% | 2717 |
|
|
2023
Q4 | $46.2M | Buy |
1,370,668
+909,345
| +197% | +$26.6M | ﹤0.01% | 2540 |
|
|
2023
Q3 | $14.2M | Sell |
461,323
-98,033
| -18% | -$3.53M | ﹤0.01% | 2802 |
|
|
2023
Q2 | $22.4M | Buy |
559,356
+28,025
| +5% | +$1.16M | ﹤0.01% | 2363 |
|
|
2023
Q1 | $21.7M | Buy |
531,331
+91,961
| +21% | +$3.66M | ﹤0.01% | 2335 |
|
|
2022
Q4 | $17M | Buy |
439,370
+37,582
| +9% | +$1.83M | ﹤0.01% | 2511 |
|
|
2022
Q3 | $21.4M | Sell |
401,788
-26,742
| -6% | -$1.49M | ﹤0.01% | 2120 |
|
|
2022
Q2 | $25M | Buy |
428,530
+146,456
| +52% | +$9.59M | ﹤0.01% | 2038 |
|
|
2022
Q1 | $21.5M | Buy |
282,074
+43,922
| +18% | +$2.93M | ﹤0.01% | 2037 |
|
|
2021
Q4 | $14.3M | Sell |
238,152
-13,533
| -5% | -$746K | ﹤0.01% | 2519 |
|
|
2021
Q3 | $14.1M | Sell |
251,685
-171,819
| -41% | -$9.9M | ﹤0.01% | 2497 |
|
|
2021
Q2 | $25.7M | Buy |
423,504
+141,309
| +50% | +$8.94M | ﹤0.01% | 1887 |
|
|
2021
Q1 | $19.8M | Buy |
282,195
+51,345
| +22% | +$3.67M | ﹤0.01% | 1926 |
|
|
2020
Q4 | $13.8M | Buy |
230,850
+34,783
| +18% | +$2.04M | ﹤0.01% | 2181 |
|
|
2020
Q3 | $11.8M | Buy |
196,067
+66,640
| +51% | +$3.87M | ﹤0.01% | 1896 |
|
|
2020
Q2 | $6.79M | Sell |
129,427
-23,752
| -16% | -$993K | ﹤0.01% | 2346 |
|
|
2020
Q1 | $5.14M | Sell |
153,179
-93,863
| -38% | -$3.9M | ﹤0.01% | 2438 |
|
|
2019
Q4 | $11.2M | Buy |
247,042
+76,745
| +45% | +$3.26M | ﹤0.01% | 2311 |
|
|
2019
Q3 | $6.48M | Buy |
170,297
+143,633
| +539% | +$5.73M | ﹤0.01% | 2597 |
|
|
2019
Q2 | $1.16M | Sell |
26,664
-2,055
| -7% | -$87.2K | ﹤0.01% | 4146 |
|
|
2019
Q1 | $1.09M | Sell |
28,719
-230,751
| -89% | -$9.01M | ﹤0.01% | 4045 |
|
|
2018
Q4 | $11.2M | Sell |
259,470
-16,299
| -6% | -$761K | ﹤0.01% | 2015 |
|
|
2018
Q3 | $13.6M | Buy |
275,769
+166,933
| +153% | +$7.22M | ﹤0.01% | 2092 |
|
|
2018
Q2 | $3.49M | Sell |
108,836
-23,112
| -18% | -$798K | ﹤0.01% | 3566 |
|
|
2018
Q1 | $4.11M | Buy |
131,948
+10,525
| +9% | +$375K | ﹤0.01% | 3236 |
|
|
2017
Q4 | $5.54M | Buy |
121,423
+27,389
| +29% | +$1.09M | ﹤0.01% | 3011 |
|
|
2017
Q3 | $3.53M | Sell |
94,034
-85,106
| -48% | -$3.42M | ﹤0.01% | 3328 |
|
|
2017
Q2 | $8.54M | Buy |
179,140
+90,988
| +103% | +$4.22M | ﹤0.01% | 2323 |
|
|
2017
Q1 | $4.02M | Sell |
88,152
-32,416
| -27% | -$1.4M | ﹤0.01% | 3092 |
|
|
2016
Q4 | $3.89M | Buy |
120,568
+10,221
| +9% | +$341K | ﹤0.01% | 3260 |
|
|
2016
Q3 | $3.78M | Sell |
110,347
-245,919
| -69% | -$9.63M | ﹤0.01% | 2947 |
|
|
2016
Q2 | $12M | Buy |
356,266
+296,240
| +494% | +$14.6M | ﹤0.01% | 1827 |
|
|
2016
Q1 | $3.18M | Sell |
60,026
-60,588
| -50% | -$3.54M | ﹤0.01% | 2933 |
|
|
2015
Q4 | $9.26M | Buy |
120,614
+26,865
| +29% | +$1.52M | ﹤0.01% | 2056 |
|
|
2015
Q3 | $3.85M | Buy |
93,749
+29,166
| +45% | +$1.79M | ﹤0.01% | 2888 |
|
|
2015
Q2 | $4.57M | Sell |
64,583
-11,827
| -15% | -$931K | ﹤0.01% | 2868 |
|
|
2015
Q1 | $6.79M | Sell |
76,410
-77,586
| -50% | -$7.87M | ﹤0.01% | 2454 |
|
|
2014
Q4 | $13.7M | Buy |
153,996
+55,035
| +56% | +$5.21M | 0.01% | 1778 |
|
|
2014
Q3 | $9.59M | Buy |
98,961
+55,349
| +127% | +$5.38M | ﹤0.01% | 2057 |
|
|
2014
Q2 | $4.01M | Sell |
43,612
-61,259
| -58% | -$4.66M | ﹤0.01% | 2872 |
|
|
2014
Q1 | $7.34M | Buy |
104,871
+76,553
| +270% | +$5.21M | ﹤0.01% | 2215 |
|
|
2013
Q4 | $1.63M | Sell |
28,318
-7,851
| -22% | -$413K | ﹤0.01% | 3533 |
|
|
2013
Q3 | $1.74M | Buy |
36,169
+8,084
| +29% | +$295K | ﹤0.01% | 3343 |
|
|
2013
Q2 | $814K | Buy |
+28,085
| New | +$812K | ﹤0.01% | 3885 |
|
Other funds holding PCRX
DPCM
VPM
VCM
Morgan Stanley's PCRX Position: Q1 2026 in Review
Morgan Stanley increased its Pacira BioSciences (PCRX) stake by 17% in Q1 2026, buying an estimated $4.44M and bringing the position to 1,392,548 shares worth $31.5M. The position accounts for ﹤0.01% of the portfolio, ranked #2535.
Morgan Stanley first reported a position in PCRX in Q2 2013 and has held it in 52 quarters since. The position peaked at $46.2M in Q4 2023. 241 funds tracked by Wall St. Rank hold PCRX as of Q1 2026.
- Morgan Stanley held 1,392,548 shares of Pacira BioSciences worth $31.5M as of Q1 2026.
- Morgan Stanley bought 199,954 Pacira BioSciences shares in Q1 2026, an estimated $4.44M.
- Pacira BioSciences made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #2535 holding.
- Morgan Stanley first reported a position in Pacira BioSciences in Q2 2013 and has held it in 52 quarters since.
- Morgan Stanley's Pacira BioSciences position peaked at $46.2M in Q4 2023.
- 241 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2026.
Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.